Date: 2013-04-10
Type of information: Presentation of results at a congress
phase: 2
Announcement: presentation of results at the AACR Annual meeting
Company: Activartis Biotech (Austria)
Product: AV0113 (IL-12-secreting dendritic cells loaded with autologous tumour lysate)
Action
mechanism: cell therapy/immunotherapy product. AV0113 is a cancer immunotherapy.
Disease: glioma
Therapeutic area: Cancer - Oncology
Country: Austria
Trial
details: The GBM-Vax study has been designed to provide evidence for the effectiveness of AV0113 cancer immunotherapy. This randomised, open-label, two-arm, multi-centre, phase II clinical study being is conducted at eight neuro-surgery/neuro-oncology institutions in Austria, three of them being university hospitals. Patients receive first-line standard therapy with or without AV0113 cancer immuno-therapy as an add-on treatment. In the randomised treatment group, AV0113 is administered as an add-on. It is inoculated into inguinal lymph nodes: after six weeks of chemo and radiotherapy, four weekly applications; accompanying the maintenance chemotherapy, six more applications every 4 weeks; finally one boost immunisation every three months as long as DC-CIT is available. (NCT01213407)
Latest
news: At the beginning of 2013, Activartis completed recruitment of around 100 brain cancer patients for a multi-centre, randomised, phase II clinical trial. This randomised study aims to deliver safety and efficacy data for the first time. Early results do not exhibit an improvement in progression-free survival, but overall survival seems to clearly favour GBM patients. Preliminary results presented at the AACR Annual Meeting (April 6-10, 2013, Washington) revealed a very promising trend suggesting a survival benefit of patients in the AV0113 treatment group compared to the randomised control group. This was notably the case for a subgroup for which, although only one third of the patients were available for assessment at this time, the difference in overall survival appeared to be quite remarkable.
At 12 months, 21/33 (64 %) of patients in the treatment group and 17/35 (48 %) of patients in the control group were still alive. At 18 months, 8/15 (50 %) of patients in the treatment and 6/18 (33 %) of patients in the control group were still alive.
Patients receiving AV0113 cancer immunotherapy tended to experience signs of relapse earlier compared to control patients. AV0113-triggered inflammation in the tumour tissue may explain this observation, which was also made in other clinical trials studying cancer immunotherapy. When tumour growth is controlled by cancer immunotherapy, this is accomplished by inflammation, thereby resulting in a larger oedema and infiltration with immune cells. This may very easily result in pressure-induced neurological symptoms, which then are wrongly interpreted as “progression”. True progression would go along with reduced overall survival – preliminary results of the on-going study, however, suggest that overall survival may in fact be positively influenced.
AV0113 treatment was well tolerated; no serious adverse events were noted that could clearly be attributed to DC-CIT. Inoculation into inguinal lymph nodes causes local swelling, redness and tenderness; some of the patients ran a temperature of around 40°C. Although these are early data, Activartis has already concluded that the DC-CIT treatment is well tolerated. Confirmation of that trend is expected in the second half of 2013. If the trend currently observed is confirmed, AV0113 is bound to become part of the standard therapy for GBM.
